Skip to main content

AstraZeneca invests in Imperial's self-amplifying RNA technology with eye on future drugs

AstraZeneca has struck a deal with the firm behind Imperial College London's experimental Covid-19 vaccine.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.